Nicoletta Eliopoulos

Title: The Innovations of Nicoletta Eliopoulos

Introduction

Nicoletta Eliopoulos is a prominent inventor based in Montreal, Canada. She has made significant contributions to the field of genetic engineering, particularly through her innovative work on cytidine deaminase. Her research has important implications for gene therapy, especially in treating malignant, immune, and viral diseases.

Latest Patents

Nicoletta holds a patent for "Cytidine deaminase cDNA as a positive selectable marker for gene." This invention involves a DNA sequence for the human cytidine deaminase that has been engineered into an eukaryotic expression vector. This advancement allows for the expression of cytidine deaminase in mammalian cells, conferring resistance to cytosine nucleoside analogs, such as cytosine arabinoside. The expression of cytidine deaminase protects cells from the toxic effects of these analogs, providing a valuable tool for gene therapy applications.

Career Highlights

Nicoletta Eliopoulos is affiliated with Hôpital Sainte-Justine, where she continues her research and development in the field of genetic engineering. Her work has garnered attention for its potential to improve therapeutic strategies in medicine.

Collaborations

Some of her notable coworkers include Richard Lewis Momparler and Josée Laliberté. Their collaborative efforts contribute to the advancement of research in genetic therapies.

Conclusion

Nicoletta Eliopoulos is a trailblazer in the field of genetic engineering, with her innovative patent on cytidine deaminase showcasing her commitment to advancing medical science. Her contributions are paving the way for new therapeutic approaches in treating various diseases.